You are here

Jardiance

J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances

J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances

Fierce Pharma

Boehringer Ingelheim

Flag link:

BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits

BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits

Fierce Pharma

Boehringer Ingelheim

DTC advertising

Flag link:

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Medical Marketing and Media

Flag link:

AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study

AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study

Fierce Pharma

Boehringer Ingelheim

Flag link:

J&J's Invokana lowers CV risk, but by enough to compete?

J&J's Invokana lowers CV risk, but by enough to compete?

BioPharma Dive

Boehringer Ingelheim

Flag link:

ADA: Merck, Pfizer notch success, but late with SGLT-2 data

ADA: Merck, Pfizer notch success, but late with SGLT-2 data

BioPharma Dive

SGLT2 inhibitor

Boehringer Ingelheim

Flag link:

J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes

J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes

Forbes

amputation. Eli Lilly

Boehringer Ingelheim

Flag link:

ADA preview: 5 things to watch in diabetes

ADA preview: 5 things to watch in diabetes

BioPharma Dive

Boehringer Ingelheim

PCSK9 inhibitors

Amgen Regeneron

Flag link:

2 Reasons Eli Lilly is Getting Crushed

2 Reasons Eli Lilly is Getting Crushed

Barron's

Flag link:

Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis

Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis

Fierce Pharma

Boehringer Ingelheim

SGLT2 inhibitor

Flag link:

Merck and Pfizer prep for battle with SGLT2, combo diabetes filings

Merck and Pfizer prep for battle with SGLT2, combo diabetes filings

Fierce Pharma

SGLT2 inhibitor

Boehringer Ingelheim

Flag link:

ADA guidelines highlight new Jardiance label

ADA guidelines highlight new Jardiance label

BioPharma Dive

Boehringer Ingelheim

Flag link:

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

Medical Marketing and Media

Boehringer Ingelheim

Flag link:

Lilly Shares Spike On Jardiance Approval (LLY)

Lilly Shares Spike On Jardiance Approval (LLY)

Investopedia

type 2 diabetes

cardiovascular death

Flag link:

Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication

Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication

Fierce Pharma

Boehringer Ingelheim

Flag link:

Eli Lilly Has Catalysts Ahead

Eli Lilly Has Catalysts Ahead

TheStreet.com

Flag link:

U.S. panel backs claim Lilly diabetes drug cuts cardiac death

U.S. panel backs claim Lilly diabetes drug cuts cardiac death

Yahoo/Reuters

advisory panels

Boehringer Ingelheim

Flag link:

Is Merck & Co., Inc Januvia In Trouble? FDA Panel Decides Tomorrow

Is Merck & Co., Inc Januvia In Trouble? FDA Panel Decides Tomorrow

Bidness, ETC

advisory panels

Flag link:

FDA panel to vote whether diabetes drug cuts cardiac death

FDA panel to vote whether diabetes drug cuts cardiac death

Yahoo/Reuters

advisory panels

Boehringer Ingelheim

Flag link:

Eli Lilly Shows Terrific Innovation

Eli Lilly Shows Terrific Innovation

Seeking Alpha

Flag link: